Ticker Hub
LIVN — AI Analysis & Sentiment
3 recent AI-generated analyses for LIVN. Sentiment and confidence insights updated continuously.
Annals of Internal Medicine Publishes 12-Month Results from LivaNova’s OSPREY Clinical Study for Obstructive Sleep Apnea
The publication of positive 12-month OSPREY study results validates LivaNova's FDA-approved OSA device, aura6000. This strong clinical data should ...
Apr 20, 2026LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LivaNova's FDA approval for the aura6000 System marks a critical step for its sleep apnea therapy, offering a competitive advantage in a growing ma...
Mar 19, 2026LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LivaNova reported robust adjusted financial performance and issued optimistic future guidance, supported by significant regulatory and clinical adv...
Feb 27, 2026